Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study. J of Skin [Internet]. 2019 Nov. 9 [cited 2025 May 18];3:S35. Available from: https://skin.dermsquared.com/skin/article/view/762